Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19

Bibliographic Details
Main Author:	Melvin Khee Shing Leow
Format:	Article
Language:	English
Published:	BMC 2020-07-01
Series:	Critical Care
Online Access:	http://link.springer.com/article/10.1186/s13054-020-03097-w

Similar Items

Profiling Levels of Serum microRNAs and Soluble ACE2 in COVID-19 Patients
by: Noha Mousaad Elemam, et al.
Published: (2022-04-01)

Is Self-Determined Motivation a Useful Agent to Overcome Perceived Exercise Barriers in Patients With Type 2 Diabetes Mellitus?
by: Heon Jin Kang, et al.
Published: (2021-06-01)

The role of infrared thermography (IRT) and magnetic resonance imaging (MRI) in brown fat evaluation and their application to study the effect of thyroid status on brown fat activity and white fat partitioning
by: Leow, Melvin Khee Shing
Published: (2020)

Editorial: Thyroid hormones and cardiac arrhythmia
by: Johannes W. Dietrich, et al.
Published: (2022-09-01)

Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence
by: Patrick Müller, et al.
Published: (2022-08-01)

Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
by: Mikhail Lebedin, et al.
Published: (2024-03-01)

Age and sex differences in soluble ACE2 may give insights for COVID-19
by: Per Swärd, et al.
Published: (2020-05-01)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
by: Ikram Omar Osman, et al.
Published: (2021-06-01)

Concentrations of Soluble Angiotensin Converting Enzyme 2 (sACE2) in Children and Adults with and without COVID-19
by: Sarah Isabella Wissing, et al.
Published: (2022-11-01)

ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
by: Federica Saponaro, et al.
Published: (2020-09-01)

ACE and ACE2: insights from Drosophila and implications for COVID-19
by: Paul Herrera, et al.
Published: (2021-12-01)

Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls
by: Josefina Robertson, et al.
Published: (2022-12-01)

ACE2, Metformin, and COVID-19
by: Atul Malhotra, et al.
Published: (2020-09-01)

Interconversion of Plasma Free Thyroxine Values from Assay Platforms with Different Reference Intervals Using Linear Transformation Methods
by: Fanwen Meng, et al.
Published: (2021-01-01)

Oxytocin in metabolic homeostasis : implications for obesity and diabetes management
by: Ding, C., et al.
Published: (2020)

Interconversion of plasma free thyroxine values from assay platforms with different reference intervals using linear transformation methods
by: Meng, Fanwen, et al.
Published: (2021)

Increased Consumption of Unsaturated Fatty Acids Improves Body Composition in a Hypercholesterolemic Chinese Population
by: Sumanto Haldar, et al.
Published: (2022-04-01)

The Role of ACE, ACE2, and AGTR2 Polymorphisms in COVID-19 Severity and the Presence of COVID-19-Related Retinopathy
by: Kristina Jevnikar, et al.
Published: (2022-06-01)

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer
by: Robert H. Shoemaker, et al.
Published: (2022-01-01)

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer.
by: Robert H Shoemaker, et al.
Published: (2022-01-01)

Prediction of subclinical atherosclerosis in low Framingham risk score individuals by using the metabolic syndrome criteria and insulin sensitivity index
by: Benjamin Huang, et al.
Published: (2022-10-01)

Increased Thrombotic Risk in COVID-19: Evidence and Controversy
by: Antonio De Vita, et al.
Published: (2023-07-01)

Engineered soluble ACE2 receptor: Responding to change with change
by: Guangyao Li, et al.
Published: (2023-01-01)

Haematological Profile and ACE2 Levels of COVID-19 Patients in a Metropolis in Ghana
by: Ezekiel B. Ackah, et al.
Published: (2024-01-01)

ACE2 Shedding and the Role in COVID-19
by: Jieqiong Wang, et al.
Published: (2022-01-01)

The ACE-2 in COVID-19 : foe or friend?
by: Dalan, Rinkoo, et al.
Published: (2021)

Asking clarifying questions: to benefit or to disturb users in web search?
by: Zou, Jie, et al.
Published: (2023)

Genotype variation of ACE and ACE2 genes affects the severity of COVID-19 patients
by: Ingrid Faustine, et al.
Published: (2023-09-01)

Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease.
by: Maria Sabater Molina, et al.
Published: (2022-01-01)

COVID-19: No end to controversies
by: Mahendra Singh, et al.
Published: (2020-01-01)

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
by: Mina K. Chung, et al.
Published: (2020-08-01)

The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19
by: Mira Bosso, et al.
Published: (2020-09-01)

Evaluation of an artificial pancreas in in silico patients with online-tuned internal model control
by: Cho, Namjoon, et al.
Published: (2018)

ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)?
by: Pasquale Pagliaro, et al.
Published: (2020-06-01)

Is Covid-19 Severity Associated With ACE2 Degradation?
by: Ugo Bastolla, et al.
Published: (2022-01-01)

COVID-19 susceptibility: potential of ACE2 polymorphisms
by: Mayank Chaudhary
Published: (2020-09-01)

Higher Soluble ACE2 Levels and Increased Risk of Infection-Related Hospitalization in Patients on Maintenance Hemodialysis
by: Mayuko Kawabe, et al.
Published: (2022-01-01)

Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)
by: Alice G. Vassiliou, et al.
Published: (2021-07-01)

The association of ACE1, ACE2, TMPRSS2, IFITM3 and VDR polymorphisms with COVID-19 severity
by: Zorana Dobrijević, et al.
Published: (2022-06-01)

Personalized glucose-insulin model based on signal analysis
by: Goede, Simon L., et al.
Published: (2017)